Pfizer names head of oncology as new R&D chief
by
Contributor since / Followers
Contributor since / Followers
9 hours ago
JHVEPhoto/iStock Editorial via Getty Images Pfizer (NYSE:PFE) on Wednesday promoted Chris Boshoff, the executive in
PFE
Pfizer, Arvinas delay late-stage trial for breast cancer therapy
by
Contributor since / Followers
Contributor since / Followers
1 day ago
bymuratdeniz Arvinas (NASDAQ:ARVN) announced that the company and its partner, Pfizer (NYSE:PFE), decided to postpone
Big Pharma Reckoning Looms With RFK Jr. Eyeing Pfizer
by Grassroots Trading
Contributor since 2016 / 695 Followers
Contributor since 2016 / 695 Followers
5 days ago
Summary: RFK Jr.’s potential appointment as Health Secretary could increase scrutiny on Pfizer Inc., impacting
Pfizer reportedly eyeing sale of hospital drugs unit
by
Contributor since / Followers
Contributor since / Followers
1 week ago
JHVEPhoto/iStock Editorial via Getty Images Pfizer (NYSE:PFE) has hired Goldman Sachs to gauge initial buyer
AbbVie And Pfizer: Q3 Dividend Checkup Post-Earnings
by Sensor Unlimited
Contributor since 2021 / 8833 Followers
Contributor since 2021 / 8833 Followers
1 week ago
Summary: I review both AbbVie and Pfizer’s recent earnings reports via the window of dividends
Pfizer: Do Not Be Fooled By 6%+ Dividend Yield
by KM Capital
Contributor since 2024 / 3040 Followers
Contributor since 2024 / 3040 Followers
1 week ago
Summary: Pfizer’s stock underperforms the S&P 500, facing patent expirations and competition, yet offers a
Pfizer: The Tide Finally Turning
by Jason Fieber
Contributor since 2013 / 3649 Followers
Contributor since 2013 / 3649 Followers
1 week ago
Summary: Pfizer, a multinational pharmaceutical and biotechnology corporation, is now a $159 billion (by market
Pfizer to invest $1B in China over next five years
by
Contributor since / Followers
Contributor since / Followers
2 weeks ago
Golden_Brown The head of Pfizer’s (NYSE:PFE) operations in China said the global pharmaceutical company will
Pfizer: Discounted For A Reason – But Dividend Story Remains Rich
by Juxtaposed Ideas
Contributor since 2022 / 12397 Followers
Contributor since 2022 / 12397 Followers
2 weeks ago
Summary: PFE’s core portfolio and strategic acquisitions continue to deliver decent results, no matter the
Pfizer, GSK, Moderna struggle in a shrinking RSV vaccine market
by
Contributor since / Followers
Contributor since / Followers
2 weeks ago
Peter Hansen/iStock via Getty Images Moderna’s (NASDAQ:MRNA) Q3 results confirmed on Thursday that the U.S.